Skip to main content

Month: April 2020

Reykjavik Energy: Planned bond issuance 2020

In a press release on April 8th regarding actions taken by Reykjavik Energy (OR) and its subsidiaries due to Covid-19, it was stated that OR‘s Board of Directors had that same day approved to increase the company‘s authorization for financing in the form of bonds, bills or bank loans from ISK 13bn to up to ISK 30bn. As stated in the press release, the reasons for this increased financing need are increased investments and dividend payments and generally worse economic conditions overall. In addition, a part of this increase will be allocated to refinancing loans from OR‘s owners.OR has a very strong strong financial position, with a cash position of over ISK 21bn in addition to access to credit lines of ISK 7bn through 2020. The company is operationally robust and well positioned for adverse business conditions for the foreseeable future....

Continue reading

Orkuveita Reykjavíkur: Fyrirhuguð skuldabréfaútgáfa 2020

Í tilkynningu þann 8. apríl sl. um aðgerðir Orkuveitu Reykjavíkur og dótturfélaga vegna Covid-19 kom fram að stjórn félagsins hafði á fundi sínum sama dag samþykkt að auka heimild til fjármögnunar í formi skuldabréfaútgáfu, víxlaútgáfu eða bankalána úr 13 milljörðum króna á árinu 2020 í allt að 30 milljarða króna. Eins og fram kom í tilkynningunni er ástæða þessarar auknu fjármögnunarþarfar auknar fjárfestingar og arðgreiðslur ásamt væntingum um verri efnahagshorfur almennt. Þá er einnig gert ráð fyrir endurgreiðslu á lánum til eigenda félagsins.Staða Orkuveitunnar er sterk um þessar mundir en sjóðsstaða nemur rúmum 21 milljarði króna. Jafnframt hefur félagið aðgang að lánalínum að fjárhæð 7 milljarða króna út árið 2020. Félagið er vel rekstarhæft og getur tekið á sig áföll um fyrirsjáanlega framtíð. Fyrirtækið hefur gert mjög ströng...

Continue reading

Aktietilbagekøb i Danske Andelskassers Bank A/S – transaktioner i uge 15

Selskabsmeddelelse nr. 21/2020 | 14. april 2020Den 1. oktober 2019 iværksatte Danske Andelskassers Bank A/S’ (”Banken”) et aktietilbagekøbsprogram. Aktietilbagekøbsprogrammet løber i perioden fra 1. oktober 2019 til 30. september 2020. I denne periode vil Banken opkøbe aktier for en maksimal værdi af 16.898.800 kroner, jf. selskabsmeddelelse nr. 18 af 24. september 2019.Under aktietilbagekøbsprogrammet er følgende transaktioner gennemført:Efter ovenstående transaktioner ejer Banken i alt 1.745.950 egne aktier svarende til 1,0009 % af Bankens aktiekapital.Siden aktietilbagekøbsprogrammet blev iværksat den 1. oktober 2019, er der samlet købt 1.527.233 aktier for et samlet beløb på 10.869.138,00 kroner.Alle transaktioner er foretaget i ISIN DK0060299063.Vedhæftet fil21-2020 Selskabsmeddelelse_Aktietilbagekøb uge 15

Continue reading

Wessanen shareholders can voluntarily transfer their shares to Bidco before 7 May 2020

This is a joint press release by PAI Partners SAS (“PAI”) and various entities (indirectly) controlled by or affiliated to Charles Jobson and/or his family members (“Charles Jobson”), acting jointly through Best of Nature Bidco B.V. (“Bidco”, and together with PAI and Charles Jobson, the “Consortium”) and Wessanen B.V. (previously named: Koninklijke Wessanen N.V.) (“Wessanen”).Wessanen shareholders can voluntarily transfer their shares to Bidco before 7 May 2020Judgment rendered by the Enterprise Chamber in the squeeze-out proceedings on Wessanen sharesPrice per share equal to offer price of EUR 11.36 plus statutory interest as of 30 September 2019Voluntary transfer of shares to Bidco possible between 14 April 2020 and 7 May 2020, at 15:00 hours CETTransfer by operation of law into consignment for shares not voluntary transferred will occur...

Continue reading

BOURSE DIRECT : Bourse Direct Horizon reçoit l’oscar du meilleur fonds Euro-Croissance

     Bourse Direct Horizon reçoit  L’OSCAR DU « MEILLEUR FONDS EURO-CROISSANCE »Une nouvelle récompense pour le contrat d’assurance vie de Bourse DirectBourse Direct est récompensé pour la 2ème année consécutive d’un Oscar pour son produit d’assurance vie. Bourse Direct Horizon remporte l’Oscar du meilleur contrat d’assurance vie nouvelle génération dans la catégorie « Meilleur fonds euro-croissance », décerné par Gestion de Fortune, le magazine de référence de la Gestion Privée.Chaque année, le jury des Oscars de l’assurance vie, composé de personnalités reconnues dans le monde de l’assurance et de la gestion privée, ainsi que de journalistes de Gestion de Fortune, récompensent les meilleurs contrats du marché.Les fonds Euro-croissance, ces fonds dits « nouvelle génération »  Les fonds Euro-croissance sont complémentaires...

Continue reading

MegumaGold Provides Update on Osprey Acquisition and Its Projects

HALIFAX, Nova Scotia, April 14, 2020 (GLOBE NEWSWIRE) — MegumaGold Corp. (CSE: NSAU, OTC: NSAUF, FWB: 2CM2) (“MegumaGold” or the “Company”) is pleased to provide the following updates on its on-going corporate and exploration activities.Osprey Gold Acquisition UpdateThe Company continues its discussions with Osprey Gold Development Ltd. (“Osprey Gold”) regarding the proposed business combination transaction whereby the Company will acquire 100% of the issued and outstanding shares of Osprey Gold (the “Proposed Transaction”). Details of the Proposed Transaction are described in a Company press release dated March 23, 2020. Each of the Company and Osprey Gold remain committed to consummating the Proposed Transaction and the parties are currently in the process of finalizing the terms of a definitive agreement.Touquoy WestThe Company...

Continue reading

UPS Expedites Global Deliveries Of QIAGEN Coronavirus Testing Kits

BRUSSELS, BELGIUM, April 14, 2020 (GLOBE NEWSWIRE) —QIAGEN dramatically ramping up production capacity to get testing solutions to labs and hospitals across the world via UPS’s smart global logistics networkUPS helping QIAGEN deploy products worldwide, including the first syndromic testing solution that can differentiate novel Coronavirus from 20 other serious respiratory infections in approximately one hourUPS (NYSE:UPS), a global leader in logistics, today announced that it is working with QIAGEN, a leading global provider of molecular diagnostics and sample preparation technologies, to deliver nucleic acid extraction kits critical to COVID-19 testing, as well as its novel QIAstat-Dx Coronavirus testing cartridges to destinations around the world. With governments and public authorities classifying UPS as an essential service...

Continue reading

INVESTORS HOUSEN TJ PETRI ROININEN: KRIISI MUUTTAA ASUMISTA – EI PALUUTA VANHAAN

 Investors House Oyj                                                                         14.4.2020Lehdistötiedote 14.4.2020 klo 9.25INVESTORS HOUSEN TJ PETRI ROININEN: KRIISI MUUTTAA ASUMISTA – EI PALUUTA VANHAANJokainen kriisi on muuttanut asumista – niin tapahtuu nytkinSodan jälkeinen jälleenrakennusaika jakoi ihmiset kahteen kastiin – omistus- ja vuokra-asujiin. Syntyi käsite kaupungin vuokratalo, joka paitsi antoi mahdollisuuden pienituloisille asua samoilla alueilla muiden kanssa myös leimasi asujiaan. Se myös torjui tehokkaasti segregaatiota ennen kuin sanaa oli edes keksitty. Kaiken ohessa siirtokarjalaiset – yli 400.000 ihmistä ja yhdeksän prosenttia koko väestöstä – asutettiin huutavasta asuntopulasta huolimatta. Kaikesta selvittiin.1990-luvun lama ja pankkikriisi romahduttivat asuntojen arvot ja nostivat korot korkeuksiin....

Continue reading

Eurobio Scientific : STRONG GROWTH OF 2019 ANNUAL RESULTS

STRONG GROWTH OF 2019 ANNUAL RESULTS+40% growth of EBITDA at 7 M€Positive net result at 3.2 M€ (vs -2.8 M€ in 2018)Paris, April 14, 2020 – 8:00 amEurobio Scientific (FR0013240934, ALERS, eligible PEA-PME), a leading French group in the field of specialty in vitro medical diagnostics, presents today its 2019 consolidated annual results which were established according to French accounting standards and were approved by the company’s board of directors which met on April 13, 20201.Strong growth of overall resultsEurobio Scientific presents annual results for 2019 which confirm the achievement of its growth and profitability targets almost a year ahead of schedule. 2019 sales reached € 59.1 million, i.e. almost the 25% target of overall sales growth expected between 2017 and 2020. On a comparable basis, excluding sales of Pathway and...

Continue reading

Eurobio Scientific : RESULTATS ANNUELS 2019 EN FORTE PROGRESSION

RESULTATS ANNUELS 2019 EN FORTE PROGRESSION+40% de croissance de l’EBITDA à 7 M€Résultat net positif à 3,2 M€ (vs -2,8 M€ en 2018)Paris, le 14 avril 2020 – 8h00Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de spécialité, présente aujourd’hui ses résultats annuels consolidés 2019 qui sont établis selon les normes françaises et ont été arrêtés par le conseil d’administration de la société qui s’est réuni le 13 avril 20201.Forte progression de l’ensemble des résultatsEurobio Scientific présente des résultats annuels 2019 qui confirment la réalisation de ses objectifs de croissance et de rentabilité en avance de presque une année sur son calendrier. Le chiffre d’affaires 2019 atteint 59,1 M€, c’est à dire quasiment l’objectif de 25% de croissance globale des ventes...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.